bioAffinity Technologies Inc
For the period ended Dec 31, 2023. Filed Apr 1, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Apr 1, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Signatures
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized on the 1 st day of April, 2024.
| bioAffinity Technologies, Inc. | |
| By: | /s/ Maria Zannes |
| Maria Zannes | |
| Chief Executive Officer, President, and Director |
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.
| Signature | Title | Date |
|---|---|---|
| /s/ Maria Zannes | President, Chief Executive Officer, and Director (Principal Executive Officer) | April 1, 2024 |
| Maria Zannes | ||
| /s/ Michael Dougherty | Chief Financial Officer | April 1, 2024 |
| Michael Dougherty | (Principal Financial and Accounting Officer) | |
| /s/ Steven Girgenti | Executive Chairman and Director | April 1, 2024 |
| Steven Girgenti | ||
| /s/ Robert Anderson | Director | April 1, 2024 |
| Robert Anderson | ||
| /s/ Stuart Diamond | Director | April 1, 2024 |
| Stuart Diamond | ||
| /s/ Peter S. Knight | Director | April 1, 2024 |
| Peter S. Knight | ||
| /s/ Gary Rubin | Director | April 1, 2024 |
| Gary Rubin | ||
| /s/ Roby Joyce, M.D. | Director | April 1, 2024 |
| Roby Joyce | ||
| /s/ Jamie Platt | Director | April 1, 2024 |
|---|---|---|
| Jamie Platt | ||
Index to the Consolidated Financial Statements
| Report of Independent Registered Public Accounting Firm (PCAOB ID NO. 100) | F-2 |
|---|---|
| Consolidated Balance Sheets as of December 31, 2023 and 2022 | F-3 |
| Consolidated Statements of Operations for the years ended December 31, 2023 and 2022 | F-4 |
| Consolidated Statements of Changes in Convertible Preferred Stock and Stockholders’ Equity for the years ended December 31, 2023 and 2022 | F-5 |
| Consolidated Statements of Cash Flows for the years ended December 31, 2023 and 2022 | F-6 |
| Notes to Consolidated Financial Statements | F-7 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.